Assessment of the Biodistribution and Safety of 123-I MZINT in Healthy Subjects and Parkinson Disease Patients
Status:
Terminated
Trial end date:
2009-10-01
Target enrollment:
Participant gender:
Summary
The overall plan of this project is to evaluate [123I] mZINT as a tool to assess SERT density
in humans. This protocol will be completed in three parts. In Part A serial dynamic SPECT
will be acquired after injection of [123I] mZINT in healthy controls to assess regional brain
uptake in human subjects. If Part A demonstrates robust brain region specific uptake, then
Part B - additional studies in healthy subjects to assess biodistribution, and Part C -
studies in PD subjects to compare regional uptake to healthy controls, will be completed.